title: Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?
authors.affiliation: Department of Neurology and Stroke Center, University Hospital Essen, Hufelandstrasse 55, D-45147 Essen, Germany h.diener@uni-essen.de.
authors.forename: Hans-Christoph
authors.initials: HC
authors.lastname: Diener
authors.affiliation: Duke Clinical Research Institute, Durham, NC, USA.
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Granger
authors.affiliation: Duke Clinical Research Institute, Durham, NC, USA.
authors.forename: Manesh R
authors.initials: MR
authors.lastname: Patel
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000150:complications*; D002545:Brain Ischemia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008297:Male; D020521:Stroke / Q000139:chemically induced*; D014859:Warfarin / Q000009:adverse effects*
chemical_list: D000925:Anticoagulants; D014859:Warfarin